目的：研究不同发育时期小鼠脑内LMO3的表达．方法：采用以SYBR Green Ⅰ为荧光染料的定量RT-PCR及以地高辛标记的cRNA为探针的原位杂交组织化学法检测LMO3基因在小鼠脑发育过程中的表达．结果：FQRT-PCR结果表明，LMO3在出生前高表达，...目的：研究不同发育时期小鼠脑内LMO3的表达．方法：采用以SYBR Green Ⅰ为荧光染料的定量RT-PCR及以地高辛标记的cRNA为探针的原位杂交组织化学法检测LMO3基因在小鼠脑发育过程中的表达．结果：FQRT-PCR结果表明，LMO3在出生前高表达，P7d后表达水平急剧下降，至成年都维持在一个较低的水平．LMO3 mRNA在小鼠胚胎期E10．5d即有表达，但仅限于整个脑泡组织内，胚体其他区域均为阴性；E11．5d脑区信号逐渐加强，无核团及脑区的特异性，胚体其他部分仍为阴性；E15．5～P0d期LMO3阳性信号在几乎所有观察的脑区均有广泛而较强的着色；P7d LMO3阳性信号较出生前变弱，分布逐渐集中；P14～P60d LMO3mRNA表达范围较P7d逐渐缩小，但仍有广泛表达，阳性信号主要集中于不同核团，表达有强弱之分．结论：LMO3基因可能与小鼠出生前脑的发育以及出生后特定脑区神经元的特化及特性维持有关．展开更多
目的探讨LMO4在弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)中的表达及其临床意义。方法应用免疫组化EnVision法检测123例DLBCL组织及60例反应性淋巴组织增生(reactive lymphoid hyperplasia,RLH)组织中LMO4蛋白的表达。...目的探讨LMO4在弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)中的表达及其临床意义。方法应用免疫组化EnVision法检测123例DLBCL组织及60例反应性淋巴组织增生(reactive lymphoid hyperplasia,RLH)组织中LMO4蛋白的表达。采用免疫细胞化学和Western blot法分别检测LMO4蛋白在DLBCL细胞株LY-10、SUDHL-4以及正常人外周血淋巴细胞中的表达。结果免疫组化结果显示LMO4蛋白在DLBCL中的高表达率明显高于RLH组织(66.7%vs 23.3%,P<0.05),其表达与肿瘤原发位置、免疫分型、IPI评分及Ann Arbor分期均有相关性(P<0.05),而与其他临床病理特征无明显相关性。免疫细胞化学和Western blot均显示LMO4在DLBCL细胞株LY-10和SUDHL-4中呈高表达,在正常人外周血淋巴细胞中呈低表达。结论DLBCL组织和细胞株中LMO4均呈高表达,在RLH和正常人外周血淋巴细胞中低表达,提示LMO4在DLBCL发生、发展中可能起重要作用。展开更多
miR-142 and miR-223 have been identified as hematopoietic specific microRNAs, miR-223 has crucial functions in myeloid lineage development. However, the function of miR-142 remains unclear. In this study, we found tha...miR-142 and miR-223 have been identified as hematopoietic specific microRNAs, miR-223 has crucial functions in myeloid lineage development. However, the function of miR-142 remains unclear. In this study, we found that both miR-142 and miR-223 attenuated the proliferation of hematopoietic cells, and that miR-223 up-regulated miR-142 expression through the LMO2-L/-S isoforms and CEBP-p. miR-223 negatively regulated both LMO2-L/-S isoforms and CEBP-β post-transcriptionally, while CEBP-βpositively regulated the LMO2-L/-S isoforms and both of the LMO2-L/-S isoforms negatively regulated miR-142. These results reveal a novel miR-223--CEBP-β-LMO2-- miR-142 regulatory pathway, which has pivotal functions in hematopoiesis.展开更多
基金This work was supported by the National Natural Science Foundation of China （Grant No. 30771054）.
文摘miR-142 and miR-223 have been identified as hematopoietic specific microRNAs, miR-223 has crucial functions in myeloid lineage development. However, the function of miR-142 remains unclear. In this study, we found that both miR-142 and miR-223 attenuated the proliferation of hematopoietic cells, and that miR-223 up-regulated miR-142 expression through the LMO2-L/-S isoforms and CEBP-p. miR-223 negatively regulated both LMO2-L/-S isoforms and CEBP-β post-transcriptionally, while CEBP-βpositively regulated the LMO2-L/-S isoforms and both of the LMO2-L/-S isoforms negatively regulated miR-142. These results reveal a novel miR-223--CEBP-β-LMO2-- miR-142 regulatory pathway, which has pivotal functions in hematopoiesis.
